Safety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study in partially reversible COPD patients
Jutta Beier1, Jan van Noord2, Amanda Deans3, Jean Brooks3, Claire Maden3, Suus Baggen4, Rashmi Mehta5, Anthony Cahn31INSAF Respiratory Research Institute, Germany; 2Atrium Medisch Centrum, The Netherlands; 3GlaxoSmithKline, Stockley Park, UK; 4GlaxoSmithKline, Zeist, The Netherlands; 5GlaxoSmithKlin...
Main Authors: | Brooks J, Deans A, Beier J, van Noord J, Cahn A, Mehta R, Baggen S, Maden C |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2012-03-01
|
Series: | International Journal of COPD |
Online Access: | http://www.dovepress.com/safety-and-efficacy-of-dual-therapy-with-gsk233705-and-salmeterol-vers-a9397 |
Similar Items
-
Superiority of tiotropium plus olodaterol in comparison with salmeterol plus fluticasone
by: Tamura T, et al.
Published: (2016-11-01) -
The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD
by: Anzueto AR, et al.
Published: (2017-05-01) -
Outcomes associated with initiation of tiotropium or fluticasone/salmeterol in patients with chronic obstructive pulmonary disease
by: Halpern R, et al.
Published: (2011-07-01) -
Evaluating the cost-effectiveness of tiotropium versus salmeterol in the treatment of chronic obstructive pulmonary disease
by: Shalini Naik, et al.
Published: (2010-03-01) -
Cost-effectiveness of combination fluticasone propionate–salmeterol 250/50 μg versus salmeterol in severe COPD patients
by: An, et al.
Published: (2010-06-01)